PH 804-TME
Alternative Names: PH 804; PH804-TME; RXI 804-TMELatest Information Update: 28 Oct 2023
At a glance
- Originator Phio Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action RNA interference; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Intratumoural, Injection)
- 10 Nov 2022 Pharmacodynamics data from preclinical studies in Solid tumours released by Phio Pharmaceuticals
- 22 Jun 2020 Pharmacodynamics data from a preclinical study in Solid tumours presented at 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)